 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on September 14, 2021, at a meeting of the Board of Directors the Board of the Company that followed the Companys 2021 Annual Meeting of Stockholders, S. Kathryn Rouan, Ph.D. retired as Chair of the Board and as a director, and Claudine Bruck, Ph.D. retired a 